Literature DB >> 22351045

Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.

John R Kapoor1, Paul A Heidenreich.   

Abstract

Tachycardia has been associated with worse outcomes for patients with heart failure and is also thought to have a direct adverse impact on the myocardium. This report highlights the current evidence for heart rate as both a risk factor and mediator for poor outcome for patients with heart failure. We summarize the large number of studies evaluating heart rate in patients with systolic dysfunction and newer studies that examine patients with preserved systolic function. The effect on outcomes in heart failure of medications known to slow the heart rate such as β-blockers and the more recently developed drug ivabradine are discussed. The data clearly show that a high heart rate is a marker of increased mortality. There is also a strong suggestion that a higher heart rate directly worsens outcome and that this can be mitigated by heart rate-reducing medications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351045     DOI: 10.1007/s11897-012-0086-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  51 in total

1.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.

Authors:  Finlay A McAlister; Natasha Wiebe; Justin A Ezekowitz; Alexander A Leung; Paul W Armstrong
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

2.  What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).

Authors:  Lars Gullestad; John Wikstrand; Prakash Deedwania; Ake Hjalmarson; Kenneth Egstrup; Uri Elkayam; Stephen Gottlieb; Andrew Rashkow; Hans Wedel; Georgina Bermann; John Kjekshus
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

3.  High heart rate: a risk factor for cardiovascular death in elderly men.

Authors:  P Palatini; E Casiglia; S Julius; A C Pessina
Journal:  Arch Intern Med       Date:  1999-03-22

4.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Authors:  Ariel Diaz; Martial G Bourassa; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  Eur Heart J       Date:  2005-03-17       Impact factor: 29.983

5.  Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

Authors:  P Lechat; S Escolano; J L Golmard; H Lardoux; S Witchitz; J A Henneman; B Maisch; M Hetzel; P Jaillon; J P Boissel; A Mallet
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

6.  Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).

Authors:  B Hedblad; J Wikstrand; L Janzon; H Wedel; G Berglund
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

7.  Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age.

Authors:  A Perski; G Olsson; C Landou; U de Faire; T Theorell; A Hamsten
Journal:  Am Heart J       Date:  1992-03       Impact factor: 4.749

8.  Retarding effect of lowered heart rate on coronary atherosclerosis.

Authors:  P A Beere; S Glagov; C K Zarins
Journal:  Science       Date:  1984-10-12       Impact factor: 47.728

9.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Authors:  Kim Fox; Ian Ford; Ph Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983

View more
  1 in total

1.  Association between process quality measures for heart failure and mortality among US veterans.

Authors:  Wen-Chih Wu; Lan Jiang; Peter D Friedmann; Amal Trivedi
Journal:  Am Heart J       Date:  2014-07-11       Impact factor: 4.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.